71
Participants
Start Date
December 31, 2013
Primary Completion Date
October 31, 2015
Study Completion Date
October 31, 2015
TRIA-662
Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
Placebo
Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
Crowfoot Village Family Practice, Calgary
Dr. Senaratne Professional Corporation, Edmonton
The Bailey Clinic, Red Deer
Manna Research Vancouver, Vancouver
GA Research Associates, Ltd, Moncton
Commonwealth Medical Clinic, Mount Pearl
Scisco Clinical Research, Cornwall
Sameh Fikry Medicine Professional Corp, Kitchener
Aging, Rehabilitation & Geriatric Care, Lawson Health Research Institute-St Joseph's Health Care, Parkwood, London
Prime Health Clinical Research, Toronto
Manna Research Inc., Toronto
Rhodin Recherche, Drummondville
Recherche Invascor, Inc., Longueuil
Montreal Heart Institute, Montreal
Clinique des Maladies Lipidiques de Quebec, Inc., Québec
Diex Recherche Sherbrooke, Sherbrooke
Centre de santé et de services sociaux de Trois-Rivières, Trois-Rivières
Lead Sponsor
Montreal Heart Institute
OTHER
Cortria Corporation
INDUSTRY